Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Epratuzumab: Final Phase II data

In an open-label, single arm, U.S. and European Phase II trial in 48 evaluable patients,

Read the full 157 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE